Saturday 17 October 2026
Export TRAW’s income statement to Excel — free account
Traws Pharma, Inc.
TRAW Healthcare Biotechnology
Traws Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, up 1,134.5% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 1.78% and free cash flow fell 25.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.37
0.03
−7.50%
Follow TRAW
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | 4 | — | — |
| (1,278.74%) | (42.56%) | (4,037.74%) | (319.42%) | ||
| (150.25%) | 38.59% | (102.21%) | (117.35%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(920.40%) | (217.25%) | 184.56% | 2,248.37% | |
Average Days of Receivables |
0.00 | 486.58 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.21) | (2.21) | (1.44) | (1.06) | |
Free Cash Flow |
(19.47) | (18.18) | (15.32) | (16.85) | |
| Other line items | |||||
Cash ROIC |
(177.54%) | (569.88%) | 703.58% | (251.22%) | |
Accounts Receivable Turnover |
0.00 | 1.02 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 426.67% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 299.44% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 25.58% | 0.00% | 0.00% | |
Operating CF/Net income |
1.21 | (2.65) | 1.10 | 1.06 | |
Depreciation/Fixed assets |
2.71 | 8.71 | 17.33 | 29.40 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.35 | 0.00 | 0.00 | |
Operating CF per Share |
(2.21) | (2.21) | (1.44) | (1.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates